Association of Inflammatory Biomarkers with Metabolic Syndrome in Hemodialysis Patients

REFERENCES

• Ucar E, Huzmeli C, Guven O, . Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions. Ren Fail. 2009;31:221–228.
   PubMed Web of Science ®Google Scholar
• Yang SY, Chiang CK, Hsu SP, . Metabolic syndrome predicts hospitalization in hemodialysis patients: A prospective Asian cohort study. Blood Purif. 2007;25:252–259.
   PubMed Web of Science ®Google Scholar
• Rasic-Milutinovic Z, Perunicic G, Pljesa S, . Metabolic syndrome in HD patients: Association with body composition, nutritional status, inflammation and serum iron. Intern Med. 2007;46:945–951.
   PubMedGoogle Scholar
• Tsangalis G, Papaconstantinou S, Kosmadakis G, . Prevalence of the metabolic syndrome in hemodialysis. Int J Artif Organs. 2007;30:118–123.
   PubMed Web of Science ®Google Scholar
• Lee CC, Lee RP, Subeq YM, . Fasting serum total ghrelin level inversely correlates with metabolic syndrome in hemodialysis patients. Arch Med Res. 2008;39:785–790.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabetes Med. 2006;23:469–480.
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T, . Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, . Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–2752.
   PubMed Web of Science ®Google Scholar
• Peralta CA, Kurella M, Lo JC, Chertow GM. The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2006;15:361–365.
   PubMed Web of Science ®Google Scholar
• Shinohara K, Shoji T, Emoto M, . Insulin resistance as an independent predictor of cardiovascular mortality in patients with endstage renal disease. J Am Soc Nephrol. 2002;13: 1894–1900.
   PubMed Web of Science ®Google Scholar
• Stolic R, Trajkovic G, Jovanovic A, . Association of metabolic changes with mortality of patients treated by peritoneal dialysis or hemodialysis. Ren Fail. 2010;32(7):778–783.
   PubMed Web of Science ®Google Scholar
• Mahajan A, Jaiswal A, Tabassum R, . Elevated levels of C-reactive protein as a risk factor for metabolic syndrome in Indians. Atherosclerosis. 2012;220(1):275–281.
   PubMedGoogle Scholar
• Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis. 2000;35(4 Suppl. 1):S117–S131.
   PubMed Web of Science ®Google Scholar
• Engström G, Lind P, Hedblad B, . Lung function and cardiovascular risk: Relationship with inflammation-sensitive plasma proteins. Circulation. 2002;106(20):2555–2560.
   PubMed Web of Science ®Google Scholar
• Razeghi E, Parkhideh S, Ahmadi F. Khashayar 2, serum CRP levels in pre- dialysis, patient. Ren Fail. 2008;30:193–198.
   PubMed Web of Science ®Google Scholar
• Varghese K, Cherian G, Abraham UT, Hayat NJ, Johny KV. Predictors of coronary disease in patients with end stage renal disease. Ren Fail. 2001;23(6):797–806.
   PubMed Web of Science ®Google Scholar
• Rutter MK, Meigs JB, Sullivan LM, . C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study. Circulation. 2004;110(4): 380–385.
   PubMed Web of Science ®Google Scholar
• Wilson PWF, D’Agostino RB, Parise H, . Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066–3072.
   PubMed Web of Science ®Google Scholar
• Ye X, Yu Z, Li H, . Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. J Am Coll Cardiol. 2007;49(17):798–805.
   Google Scholar
• Mahadik SR, Deo SS, Mehtalia SD. Relation of C-reactive protein with the components of metabolic syndrome in Asian Indian subjects. Diabetes Metab Syndr Res Rev. 2008;2(1):29–35.
   Google Scholar
• Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord. 2001;25(9):1327–1331.
   PubMedGoogle Scholar
• Festa A, DÁgostino Jr R, Howard G, . Chronic subclinical inflammation as a part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42–47.
   PubMed Web of Science ®Google Scholar
• Frohlich M, Imhof A, Berg G, . Association of C-reactive protein and features of metabolic syndrome: A population based study. Diabetes Care. 2000;23(12):1835–1839.
   PubMed Web of Science ®Google Scholar
• Esmaillzadeh A, Mirmiran P, Azadbakht L, Etemadi A, Azizi F. High prevalence of the metabolic syndrome in Iranian adolescents. Obesity. 2006;14(3):377–382.
   PubMedGoogle Scholar
• Ghassemi H, Harrison G, Mohammad K. An accelerated nutrition transition in Iran. Public Health Nutr. 2002;5:149–155.
   PubMed Web of Science ®Google Scholar
• Hsu CY, McCulloch CE, Iribarren C, . Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–28.
   PubMed Web of Science ®Google Scholar
• Williams JD, Woods HF. Insulin resistance, the metabolic syndrome and renal failure – Is there a special problem for patients treated with peritoneal dialysis? Eur Endocrine Rev. 2006;15:54–59.
   Google Scholar
• Bakker SL, Gansevoort RT, Zeeuw DD. Metabolic syndrome: A fata morgana? Nephro Dial Transplant. 2007;22:15–20.
   PubMedGoogle Scholar
• Young DO, Lund RJ, Haynatzki G, Dunlay RW. Prevalence of the metabolic syndrome in an incident dialysis population. Hemodial Int. 2007;11:86–95.
   PubMedGoogle Scholar
• Armstrong KA, Hiremagalur B, Haluska BA, . Free fatty acids are associated with obesity, insulin resistance, and atherosclerosis in renal transplant recipients. Transplantation. 2005;80:937–944.
   PubMedGoogle Scholar
• Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant. 2005;5:2710–2718.
   PubMed Web of Science ®Google Scholar
• Elsaid SA, Hamada MA, Alsaran KA. Obesity and metabolic syndrome in Saudi hemodialysis patients. JNRT. 2009;2:18–27.
   Google Scholar
• Stoli R, Trajkovi G, Peri V, . Frequency and characteristics of metabolic disorders in patients on hemodialysis. Vojnosanit Pregl. 2008;65:205–209.
   PubMedGoogle Scholar
• Salmenniemi U, Ruotsalainen E, Pihlajamäki J, . Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004;110:3842–3848.
   PubMed Web of Science ®Google Scholar
• Choi KM, Lee J, Lee KW, . Comparison of serum concentrations of C-reactive protein, TNF-alpha, and IL 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract. 2004;64:1.
   PubMedGoogle Scholar
• Wisse BE. Inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders link to obesity. J Am Soc Nephrol. 2004;15:2792–2800.
   PubMed Web of Science ®Google Scholar
• Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: Mechanisms, mediators, and therapeutic interventions. Curr Drug Targets. 2003;4:487–492.
   PubMed Web of Science ®Google Scholar
• Collins T, Cybulsky MI. NF-kB: Pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 2001;107:255–264.
   PubMed Web of Science ®Google Scholar
• Dressner A. Insulin mediated glucose uptake in muscle, in the absence of fatty acids and in the presence of LCFACoA. J Clin Invest. 1999;103:253–259.
   PubMedGoogle Scholar
• Feldman HI, Santana J, Guo W, . Iron administration and clinical outcome in hemodialysis patients. J Am Soc Nephrol. 2002;13:734–744.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Rodrigez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in hemodialysis patients. Nephrol Dial Transplant. 2004;19:141–149.
   PubMed Web of Science ®Google Scholar
• Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Partley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001;9:414–417.
   PubMedGoogle Scholar
• Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis. 2003;169:155–158.
   PubMed Web of Science ®Google Scholar
• Maeda N, Takahashi M, Funahashi T, . PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094–2099.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW, . Markers of inflammation and cardiovascular disease. Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Yang WC, Chen HH, . National dialysis surveillance in Taiwan. Acta Nephrol. 1999;14:139–228.
   Google Scholar
• Torres JL, Ridker PM. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol. 2003;18:471–478.
   PubMed Web of Science ®Google Scholar